Incidence and remission of post-surgical cystoid macular edema following cataract surgery in eyes with intraocular inflammation.

To evaluate the incidence, remission and relapse of post-surgical cystoid macular edema (PCME) following cataract surgery in inflammatory eye disease. A total of 1859 eyes that had no visually significant macular edema prior to cataract surgery while under tertiary uveitis management were included. Standardized retrospective chart review was used to gather clinical data. Univariable and multivariable logistic regression models with adjustment for inter-eye correlations were performed. PCME causing VA 20/50 or worse was reported in 286 eyes (15%) within 6 months of surgery. Adults age 18-64 years as compared to children (adjusted Odds ratio (aOR) 2.42, for ages 18-44 and aOR 1.93 for ages 45-64, overall p = 0.02); concurrent use of systemic immunosuppression (conventional aOR 1.53 and biologics aOR 2.68, overall p =0.0095); pre-operative VA 20/50 or worse (overall p <0.0001); cataract surgery performed before 2000 (overall p=0.03) and PMCE in fellow eye (aOR 3.04, p=0.0004) were associated with development of PCME within 6 months of cataract surgery. PCME resolution was seen in 81% of eyes at 12 months and 91% of eyes at 24 months. CME relapse was seen in 12% eyes at 12 months and 19% eyes at 24 months. PCME occurs frequently in uveitic eyes undergoing cataract surgery, however, most resolve within a year. CME recurrences likely are due to the underlying disease process and not relapses of PCME.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest Sapna S. Gangaputra: National Eye Institute (Grant support); Research to Prevent Blindness (grant support, unrestricted department grant) Sylvia L. Groth: Olleyes (Grant support) Douglas A. Jabs: Abbvie (Research Funding) Grace A. Levy-Clarke: Abbvie (Consultant, Lecture Fees); Allergan (Grant Support); Mallinckrodt (Consultant, Grant Support); Sanofi (Grant Support; Lecture Fees) James T. Rosenbaum: Corvus Pharmaceuticals (Employment); Abbvie (Consultant); Gilead (Consultant); Janssen (Consultant); Eyevensys (Consultant); UpToDate (Consultant); Pfizer (Financial Support); Novartis (Consultant); Roche (Consultant); Alcon Research Institute (Financial Support); UCB (consultant); Horizon (Consultant and financial support); Santen (consultant); Celgene (Consultant); Pfizer (Education); UCB (Consultant). Eric B. Suhler: Eyevensys (Consultant); Santen (Consultant); EyeGate (Consultant, Financial Support); Abbvie (Consultant, Financial Support); Clearside (Consultant, Financial Support); EyePoint (Consultant, Financial Support) Jennifer E. Thorne: Abbvie (Consultant); Canfield (Consultant); Clearside (Consultant); Gilead (Consultant); Guidepoint (Consultant); Roche (Consultant); Tarsier Pharma (Scientific Advisory Board; Equity Owner); UptoDate (Consultant); F. Hoffmann-La Roche AG (consultant) C. Stephen Foster: Aldeyra (Consultant, Grant Support), Allakos (Consultant), Bausch & Lomb (Consultant, Grant Support), Eyegate (Consultant, Grant Support, Stock), Genentech (Consultant), Novartis (Consultant, Grant Support), pSivida (Consultant, Grant Support), Aciont (Grant Support), Alcon (Grant Support, Lecture Fees), Clearside (Grant Support), Dompé (Grant Support), Mallinckrodt (Grant Support, Lecture Fees), Allergan (Lecture Fees). John H. Kempen: Betaliq (Equity Owner); Tarsier Pharma (Equity Owner). The other authors indicate no potential conflicts of interest.